ANI Pharmaceuticals Inc. has launched Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall U.S. market for Vancomycin HCl Capsules is approximately $113 million, according to IMS Health. “We are pleased to announce the launch of our authorized generic to Vancocin, which replaces the authorized generic previously on the market,” said Arthur Przybyl, president and chief executive officer, ANI Pharmaceuticals. “This is the second ...